🎈 Up Big Today: Find today's biggest gainers (some over 50%!) with our free screenerTry Stock Screener

Glaucos CFO sells over $71k in company stock

Published 04/05/2024, 06:15 PM
GKOS
-

In recent trading activity, Alex R. Thurman, the Senior Vice President and Chief Financial Officer of Glaucos Corp (NYSE:GKOS), a leader in surgical and medical instruments, sold shares of the company's stock, totaling over $71,000. The transactions, which occurred on the 3rd and 4th of April, were executed under a pre-arranged trading plan.

Thurman sold a total of 316 shares on April 3rd at a price of $94.62 each. Following this transaction, on April 4th, additional sales were made in two separate trades: 276 shares were sold at an average price of $95.42, and another 158 shares at $95.16. The sales were part of a planned strategy, as indicated by a trading plan set up in May of the previous year.

The price range for these transactions spanned from $94.62 to $95.42. Investors following Glaucos Corp may be interested in these trades as part of keeping track of insider activity, which can provide insights into a company's financial health and executive sentiment.

Following the sales, Thurman's remaining stake in Glaucos includes 54,600 shares of common stock, which also accounts for restricted stock units that have not yet vested. As these transactions were conducted under a Rule 10b5-1 trading plan, they were likely scheduled in advance to manage insider trading concerns.

Glaucos Corp has not provided any additional comments on these transactions. Interested parties can access full details of the trades upon request, as Thurman has undertaken to provide full information regarding the number of shares sold and the prices at which the transactions were executed.

InvestingPro Insights

As investors digest the recent insider trading activity at Glaukos Corp (NYSE:GKOS), it's important to consider the broader financial context of the company. According to real-time data from InvestingPro, Glaukos has a market capitalization of approximately $4.78 billion, indicating its significant presence in the surgical and medical instruments sector. The company's Price / Book ratio stands at a high 10.36 as of the last twelve months, which could suggest a premium valuation compared to its tangible assets. Additionally, the company's revenue growth was positive, with an 11.26% increase over the last twelve months.

Offering further insights, InvestingPro Tips highlight that Glaukos is currently not profitable, with analysts not expecting profitability within this year. This aligns with the company's negative P/E ratio of -34.83, which reflects its current lack of earnings. Despite this, Glaukos has shown a strong return over the last year, with an impressive 100.89% price total return, signaling robust investor confidence and market performance. Moreover, the company's liquid assets exceed its short-term obligations, providing it with financial flexibility.

These financial metrics and insights can be particularly valuable for investors considering the implications of insider transactions. For those interested in a deeper analysis, InvestingPro Tips offer additional perspectives on Glaukos Corp, including its moderate level of debt and its trading position near the 52-week high. To explore these insights further, investors can visit InvestingPro, which provides a comprehensive list of 11 additional tips for a more informed investment decision. Use the coupon code PRONEWS24 to get an extra 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.